Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

The Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...

(RTTNews) - Sanofi (SNYNF, SNY) announced Wednesday that the US Food and Drug Administration has granted fast track designation to the company's mRNA vaccine candidate for the prevention of ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to ...